BroADen KT-621 Phase 1b AD Study Surpassed Objectives
Effects on All Type 2 Biomarkers and Clinical Endpoints Were in Line with or in Some Cases
Numerically Exceeded Published Data for Dupilumab at Week 4

                                                               BroADen
      Endpoints
                                                       Phase 1b Results Highlights

                            端 Strong fidelity of translation from Phase 1a healthy volunteer study to AD patients
  STAT6 Degradation
                                                 with deep STAT6 degradation in blood and skin


  Type 2 Biomarkers           端 Robust reductions in Type 2 biomarkers in blood, skin lesions and lung (FeNO)

                          端 Meaningful improvements of clinical endpoints and patient-reported outcomes in AD,
   Clinical Endpoints
                                                 comorbid asthma and allergic rhinitis

                             端 Well-tolerated and favorable safety profile similar to Phase 1a healthy volunteer
        Safety
                                                                    study


Clinical data continue to support a potential dupilumab-like profile in AD and other
Type 2 diseases with a once daily, oral drug
                                                                                                                    23
